Volume 22, Issue 11 (2-2024)
JRUMS 2024, 22(11): 1179-1190 |
Back to browse issues page
Ethics code: IR.RUMS.REC.1400.192
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
shafiepour M, shamsinejad S, Karimi Fard M, Ahmadinia H. Prevalence of Hypogonadism and Some Related Factors in Male Patients with Type 2 Diabetes Mellitus Referred to Ali Ibn Abi Talib Hospital of Rafsanjan in 2021:
A Descriptive Study. JRUMS 2024; 22 (11) :1179-1190
URL: http://journal.rums.ac.ir/article-1-6750-en.html
URL: http://journal.rums.ac.ir/article-1-6750-en.html
rafsanjan university of medical science
Abstract: (156 Views)
Background and Objectives: Hypogonadism is a common complication in men with type 2 diabetes. The present study aimed to determine the frequency of hypogonadism and some related factors in men with type 2 diabetes referred to the Endocrinology Clinic of Ali Ibn Abi Talib Hospital of Rafsanjan University of Medical Sciences in 2021.
Materials and Methods: In this descriptive study, 111 men with type 2 diabetes were examined. After completing the questionnaire and measuring blood pressure and waist circumference, 10 cc of fasting blood was taken to measure serum levels of total testosterone (TT), follicle stimulating hormone (FSH), luteinizing hormone (LH), and glycosylated hemoglobin (HbA1c). Data was analyzed using chi-square test, independent t-test, Pearson’s correlation test, and logistic regression.
Results: The mean and standard deviation of age of patients was 58.61±10.62 years. Twenty six patients (23.42%) had hypogonadism. With increasing body mass index, the TT levels (p=0.034), LH (p=0.008) and FSH (p=0.028) significantly decreased. With increasing HbA1c, the levels of TT (p=0.035), LH (p=0.004) and FSH (p=0.001), with increasing systolic blood pressure, the level of LH (p=0.025), and with increasing age, the levels of LH and FSH (p<0.001) significantly increased; however, with increasing waist circumference, the levels of TT (p=0.006), LH and FSH (p<0.001) significantly reduced. Mean TT (p=0.011), LH (p=0.017), and FSH (p=0.014) levels were significantly higher in those taking the drug.
Conclusion: With an increase in waist circumference, disease duration, and follicle stimulating hormone, the odds of hypogonadism increased. It is recommended to the health officials to take the necessary preventive measures including increasing the awareness of the male community.
Key words: Type 2 diabetes, Hypogonadism, Testosterone, Follicle-stimulating hormone, Luteinizing hormone, Rafsanjan
Funding: This study was funded by Rafsanjan University of Medical Sciences.
Conflict of interest: None declared.
Ethical approval: The Ethics Committee of Rafsanjan University of Medical Sciences approved the study (IR.RUMS.REC.1400.192).
How to cite this article: Shafiepour Mohammadreza, Shamsinejad Sedigheh, Karimi Fard Maryam, Ahmadinia Hassan. Prevalence of Hypogonadism and Some Related Factors in Male Patients with Type 2 Diabetes Mellitus Referred to Ali Ibn Abi Talib Hospital of Rafsanjan in 2021: A Descriptive Study. J Rafsanjan Univ Med Sci 2024; 22 (11): 1179-90. [Farsi]
Materials and Methods: In this descriptive study, 111 men with type 2 diabetes were examined. After completing the questionnaire and measuring blood pressure and waist circumference, 10 cc of fasting blood was taken to measure serum levels of total testosterone (TT), follicle stimulating hormone (FSH), luteinizing hormone (LH), and glycosylated hemoglobin (HbA1c). Data was analyzed using chi-square test, independent t-test, Pearson’s correlation test, and logistic regression.
Results: The mean and standard deviation of age of patients was 58.61±10.62 years. Twenty six patients (23.42%) had hypogonadism. With increasing body mass index, the TT levels (p=0.034), LH (p=0.008) and FSH (p=0.028) significantly decreased. With increasing HbA1c, the levels of TT (p=0.035), LH (p=0.004) and FSH (p=0.001), with increasing systolic blood pressure, the level of LH (p=0.025), and with increasing age, the levels of LH and FSH (p<0.001) significantly increased; however, with increasing waist circumference, the levels of TT (p=0.006), LH and FSH (p<0.001) significantly reduced. Mean TT (p=0.011), LH (p=0.017), and FSH (p=0.014) levels were significantly higher in those taking the drug.
Conclusion: With an increase in waist circumference, disease duration, and follicle stimulating hormone, the odds of hypogonadism increased. It is recommended to the health officials to take the necessary preventive measures including increasing the awareness of the male community.
Key words: Type 2 diabetes, Hypogonadism, Testosterone, Follicle-stimulating hormone, Luteinizing hormone, Rafsanjan
Funding: This study was funded by Rafsanjan University of Medical Sciences.
Conflict of interest: None declared.
Ethical approval: The Ethics Committee of Rafsanjan University of Medical Sciences approved the study (IR.RUMS.REC.1400.192).
How to cite this article: Shafiepour Mohammadreza, Shamsinejad Sedigheh, Karimi Fard Maryam, Ahmadinia Hassan. Prevalence of Hypogonadism and Some Related Factors in Male Patients with Type 2 Diabetes Mellitus Referred to Ali Ibn Abi Talib Hospital of Rafsanjan in 2021: A Descriptive Study. J Rafsanjan Univ Med Sci 2024; 22 (11): 1179-90. [Farsi]
Keywords: Type 2 diabetes, Hypogonadism, Testosterone, Follicle-stimulating hormone, Luteinizing hormone, Rafsanjan
Type of Study: Description |
Subject:
غدد
Received: 2022/11/1 | Accepted: 2024/02/5 | Published: 2024/02/21
Received: 2022/11/1 | Accepted: 2024/02/5 | Published: 2024/02/21
References
1. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363(2): 123-35.
2. Bebb R, Millar A, Brock G. Sexual dysfunction and hypogonadism in men with diabetes. Canadian Journal of Diabetes 2018; 42: 228-33.
3. Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic hypogonadism in men with diabesity. Diabetes Care 2018; 41(7): 1516-25.
4. Rochira V. Hypogonadism in systemic diseases. Endocrinology of the Testis and Male Reproduction 2017: 1-51.
5. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295(11): 1288-99.
6. Atlantis E, Fahey P, Martin S, O’Loughlin P, Taylor AW, Adams RJ, et al. Predictive value of serum testosterone for type 2 diabetes risk assessment in men. BMC Endocrine Disorders 2016; 16(1): 1-10.
7. Hutson J. Testis Embryology, Anatomy and Physiology. Endocrine Surgery in Children: Springer 2018; 271-9.
8. Lara NL, Costa GM, Avelar GF, Lacerda S, Hess RA, França LRd. Testis physiology-overview and histology. Encyclopedia of Reproduction; Skinner, MK, Ed; Academic Press: New York, NY, USA 2018: 105-16.
9. Patel AP. Anatomy and physiology of chronic scrotal pain. Translational Andrology and Urology 2017; 6(1): 51.
10. Livingston M, Kalansooriya A, Hartland AJ, Ramachandran S, Heald A. Serum testosterone levels in male hypogonadism: Why and when to check-A review. International Journal of Clinical practice 2017; 71(11): e12995.
11. Afkhamizadeh M, Ghaderian SB, Rajabian R, Aleali AM. Prevalence of Hypogonadotropic Hypogonadism in Type 2 Diabetes Male Patients. OJEMD 2015; 5(03): 29.
12. Misra A, Dhurandhar NV. Current formula for calculating body mass index is applicable to Asian populations. Nutr Diabetes 2019; 9(1): 3.
13. Papaioannou TG, Protogerou AD, Vrachatis D, Konstantonis G, Aissopou E, Argyris A, et al. Mean arterial pressure values calculated using seven different methods and their associations with target organ deterioration in a single-center study of 1878 individuals. Hypertension Research 2016; 39(9): 640-7.
14. Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M, Freckmann G, et al. Definition, classification and diagnosis of diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes 2019; 127(01): 1-7.
15. Mirzaei MR, Amini M, Aminorroaya A. The prevalence of hypogonadism in diabetic men in Isfahan Endocrine and Metabolism Research Center, Isfahan, Iran. J Rafsanjan Univ Med Sci 2012; 17(7): 602.
16. Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S. Hypogonadotrophic hypogonadism in type 2 diabetes. The Aging Male 2008; 11(3): 107-17.
17. Rezvani MR, Saadatjou SA, Sorouri S, Hassanpour Fard M. Comparison of serum free testosterone, luteinizing hormone and follicle stimulating hormone levels in diabetics and non-diabetics men: a case-control study. JRHS 2012; 12(2): 98-100.
18. Serwaa D, Bello FA, Osungbade KO, Nkansah C, Osei-Boakye F, Appiah SK, et al. Prevalence and determinants of low testosterone levels in men with type 2 diabetes mellitus; a case-control study in a district hospital in Ghana. PLOS Global Public Health 2021; 1(12): e0000052.
19. Souteiro P, Belo S, Oliveira SC, Neves JS, Magalhães D, Pedro J, et al. Insulin resistance and sex hormone-binding globulin are independently correlated with low free testosterone levels in obese males. Andrologia 2018; 50(7): e13035.
20. Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. The Journal of Clinical Endocrinology & Metabolism 2011; 96(9): 2643-51.
21. Yeo S, Holl K, Peñaherrera N, Wissinger U, Anstee K, Wyn R. Burden of male hypogonadism and major comorbidities, and the clinical, economic, and humanistic benefits of testosterone therapy: a narrative review. CEOR 2021; 13: 31.
22. Hussein Z, Al-Qaisi J. Effect of diabetes mellitus type 2 on pituitary gland hormones (FSH, LH) in men and women in Iraq. Al-Nahrain Journal of Science 2012; 15(3): 75-9.
23. Giagulli VA, Castellana M, Carbone MD, Pelusi C, Ramunni MI, De Pergola G, et al. Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism. Andrology 2020; 8(3): 654-62.
24. Malipatil NS, Yadegarfar G, Lunt M, Keevil B, Siddals K, Livingston M, et al. Male hypogonadism: 14-year prospective outcome in 550 men with type 2 diabetes. Endocrinology, Diabetes & Metabolism 2019; 2(3): e00064
25. Paruk IM, Pirie F, Nkwanyana N, Motala A. Prevalence of low serum testosterone levels among men with type2 diabetes mellitus attending two outpatient diabetes clinics in KwaZulu-Natal Province, South Africa. South African Medical Journal 2019; 109(12): 963-70.
26. Khripun I, Vorobyev S, Belousov I, Kogan M, Zitzmann M. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. The Aging Male 2018.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
